menu
    • menu

    Company profile for Savara

    NEW Drugs in Dev: 7
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, AeroVanc and amikacin/fosfomycin. Molgradex is an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, and in Phase 2a development for nontuberculous mycobacteria, or NTM, in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lu...
    Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, AeroVanc and amikacin/fosfomycin. Molgradex is an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, and in Phase 2a development for nontuberculous mycobacteria, or NTM, in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection. AeroVanc, is a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin-resistant Sstaphylococcus aureus, or MRSA, lung infection in CF.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    SavaraUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Savara Inc. 6836 Bee Cave Road, Building 3, Suite 200 Austin, TX, 78746
    Telephone
    Telephone
    +1 (512) 614-1848
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://savarapharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/savara-pharmaceuticals
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/SavaraPharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Savara Announces New Employee Inducement Grant
    Savara Announces New Employee Inducement Grant

    17 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260417883325/en/Savara-Announces-New-Employment-Inducement-Grant

    BUSINESSWIRE
    17 Apr 2026
    Share Share
    FDA Extends Review of Savara's Molgramostim BLA for aPAP
    FDA Extends Review of Savara's Molgramostim BLA for aPAP

    16 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7181827

    FIRSTWORD PHARMA
    16 Apr 2026
    Share Share
    FDA Extends Review Period for Savara’s Molgramostim
    FDA Extends Review Period for Savara’s Molgramostim

    15 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260415775650/en/Savara-Announces-the-U.S.-Food-Drug-Administration-FDA-Has-Extended-the-Review-Period-for-the-Molgramostim-Inhalation-Solution-Molgramostim-Biologics-License-Application-BLA-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP

    BUSINESSWIRE
    15 Apr 2026
    Share Share
    Savara To Present New Data at ATS 2026 International Conference
    Savara To Present New Data at ATS 2026 International Conference

    14 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260414233320/en/Savara-To-Present-New-Data-at-the-American-Thoracic-Society-ATS-2026-International-Conference

    BUSINESSWIRE
    14 Apr 2026
    Share Share
    Savara EMA Validates MAA MOLBREEVI Autoimmune PAP
    Savara EMA Validates MAA MOLBREEVI Autoimmune PAP

    30 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260330927904/en/Savara-Announces-European-Medicines-Agency-EMA-Validation-of-Marketing-Authorization-Application-MAA-for-MOLBREEVI-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP

    BUSINESSWIRE
    30 Mar 2026
    Share Share
    Savara Reports Fourth Quarter And Year End 2025 Financial Results
    Savara Reports Fourth Quarter And Year End 2025 Financial Results

    13 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260313815938/en/Savara-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-Business-Update

    BUSSINESSWIRE
    13 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search